These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6228936)

  • 21. DH Ergotoxin (Spofa) sublingual tablets in the treatment of cerebrovascular insufficiency in involution: clinical and experimental psychologic study.
    Misurec J; Morávek Z; Náhunek K; Cesková E; Sláma B; Svestka J
    Act Nerv Super (Praha); 1978 Dec; 20(4):266-7. PubMed ID: 367038
    [No Abstract]   [Full Text] [Related]  

  • 22. [Therapy of organic psychosyndrome with hydergine and digitalis. A component study using double blind technics].
    Pfeiff E; Schlegel HE; Seus R; Dennler HJ; Kugler J
    Med Welt; 1980 Sep; 31(39):1403-7. PubMed ID: 7005587
    [No Abstract]   [Full Text] [Related]  

  • 23. [Controlled double-blind study of the clinical equivalent of two posologic regimens of Hydergine: 1 x 4,5mg compared to 3 x 1,5mg per day].
    Piguet PV; Zoufal Z
    Rev Med Suisse Romande; 1981 Feb; 101(2):157-63. PubMed ID: 7015453
    [No Abstract]   [Full Text] [Related]  

  • 24. Event related evoked potentials in dementia.
    Breeze RW
    Br J Clin Pract Suppl; 1985 Jun; 39():43-4. PubMed ID: 3929815
    [No Abstract]   [Full Text] [Related]  

  • 25. [Psychometric evaluation of the effects of an almitrine-raubasine combination in the intellectual deterioration of aged subjects. A double-blind controlled trial versus placebo].
    Rapisarda V; Azzaro E; Fichera G
    Presse Med; 1987 Jun; 16(23):1163-6. PubMed ID: 2885827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term treatment of cerebrovascular changes in the elderly (author's transl)].
    Kugler J; Oswald WD; Herzfeld U; Seus R; Pingel J; Welzel D
    Dtsch Med Wochenschr; 1978 Mar; 103(11):456-62. PubMed ID: 631030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of organic brain psychosyndrom in the old age. A double blind study with Hydergin (author's transl)].
    Biel ML; Seus R; Struppler A
    Med Klin; 1976 Dec; 71(49):2177-84. PubMed ID: 794665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The use of Ergocomb in symptoms of cerebrovascular insufficiency].
    Pöthig D; Sauer I; Hansen H; Weidnitzer M
    Z Alternsforsch; 1983; 38(6):443-9. PubMed ID: 6659572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial.
    Rouy JM; Douillon AM; Compan B; Wolmark Y
    Curr Med Res Opin; 1989; 11(6):380-9. PubMed ID: 2651014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebral vasodilators (second of two parts).
    Cook P; James I
    N Engl J Med; 1981 Dec; 305(26):1560-4. PubMed ID: 7031468
    [No Abstract]   [Full Text] [Related]  

  • 31. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
    Hanney M; Prasher V; Williams N; Jones EL; Aarsland D; Corbett A; Lawrence D; Yu LM; Tyrer S; Francis PT; Johnson T; Bullock R; Ballard C;
    Lancet; 2012 Feb; 379(9815):528-36. PubMed ID: 22236802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydroergocryptine in the management of senile psycho-organic syndrome.
    Scarzella L; Bono G; Bergamasco B
    Int J Clin Pharmacol Res; 1992; 12(1):37-46. PubMed ID: 1526697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A dose-response study with dihydroergotoxine mesylate in cerebrovascular disturbances.
    Yoshikawa M; Hirai S; Aizawa T; Kuroiwa Y; Goto F; Sofue I; Toyokura Y; Yamamura H; Iwasaki Y
    J Am Geriatr Soc; 1983 Jan; 31(1):1-7. PubMed ID: 6336765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a levo-5-hydroxytryptophan-dihydroergocristine combination on depression and neuropsychic performance: a double-blind placebo-controlled clinical trial in elderly patients.
    Rousseau JJ
    Clin Ther; 1987; 9(3):267-72. PubMed ID: 3111702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design aspects of clinical trials with ergot alkaloids: a comparison of two geriatric behavioral rating scales.
    Yesavage JA; Adey M
    Adv Biochem Psychopharmacol; 1980; 23():357-62. PubMed ID: 7395622
    [No Abstract]   [Full Text] [Related]  

  • 36. Review of clinical studies with ergots in gerontology.
    Venn RD
    Adv Biochem Psychopharmacol; 1980; 23():363-77. PubMed ID: 7395623
    [No Abstract]   [Full Text] [Related]  

  • 37. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies.
    Saletu B; Grünberger J; Anderer R
    Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):510-24. PubMed ID: 2086492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of the effectiveness and tolerance of dihydroergotoxine and alpha methyldopa in the therapy of arterial hypertension in the elderly with senile cerebral insufficiency].
    Bergamasco B; Scarzella L; Turri D
    Recenti Prog Med; 1987 Apr; 78(4):166-70. PubMed ID: 3628936
    [No Abstract]   [Full Text] [Related]  

  • 40. Relieving select symptoms of the elderly.
    Nelson JJ
    Geriatrics; 1975 Mar; 30(3):133-9, 142. PubMed ID: 803912
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.